Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuroblastoma].

T Simon1

  • 1Pädiatrische Onkologie und Hämatologie, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universität Köln. thorsten.simon@uk-koeln.de

Der Urologe. Ausg. A
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Neuroblastoma, a childhood embryonal tumor, requires risk-adapted treatment. Survival rates vary significantly by risk group, with high-risk patients facing poorer outcomes despite intensive therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Outpatient parenteral antibiotic therapy in pediatric oncology patients with fever in neutropenia: literature review and scoping review].

Klinische Padiatrie·2026
Same author

Listening to patients: A qualitative study on diagnostic delay, coping strategies and stigma in early-onset colorectal cancer.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2025
Same author

Impact of an intensive multimodal educative program on behavioral disorders of polyhandicapped patients: A randomized controlled trial.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

Risks of early mortality and pulmonary complications following surgery in patients with COVID-19.

The British journal of surgery·2021
Same author

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Randomized clinical trial of open suture repair versus totally extraperitoneal repair for treatment of sportsman's hernia.

The British journal of surgery·2019
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Area of Science:

  • Pediatric Oncology
  • Cancer Genomics
  • Developmental Biology

Context:

  • Neuroblastoma is a common childhood embryonal tumor originating in the retroperitoneum or abdomen.
  • Catecholamine metabolites serve as crucial tumor markers for neuroblastoma detection and monitoring.
  • Advanced imaging techniques like MIBG scintigraphy, ultrasound, and MRI are vital for precise tumor visualization.

Purpose:

  • To outline the risk-adapted treatment strategy for neuroblastoma based on patient age and risk stratification.
  • To present the 5-year overall survival rates from the German NB97 trial across different risk groups.

Summary:

  • Neuroblastoma treatment must be tailored to individual risk levels, as outcomes differ significantly between young and older children.
  • The German NB97 trial demonstrated 5-year survival rates of 96% (observation), 89% (median risk), and 50% (high risk).

Related Experiment Videos

  • Spontaneous remissions occur in younger patients, but older children with neuroblastoma often have poor prognoses even with aggressive treatment.

    • Impact:

    • Highlights the critical need for risk stratification in neuroblastoma management.
    • Provides benchmark survival data from a large-scale clinical trial (NB97) for evaluating treatment efficacy.
    • Emphasizes the importance of early detection and tailored therapeutic approaches for improving pediatric cancer outcomes.